Plain-English translation of NCT07241520 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called SHPL-49 to see if it can help people recover better after an acute ischemic stroke. The medication is given as an injection over 7 days, starting within 8 hours of stroke symptoms. About half the participants will receive the real medication and half will receive a placebo (inactive injection) to fairly compare how well the treatment works.
Stroke is a medical emergency where brain cells are damaged due to blocked blood flow, and every minute matters. While doctors have emergency treatments to restore blood flow, researchers believe this medication might help protect brain cells and improve recovery if given quickly after a stroke.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either the new medication or a placebo as an injection twice daily for 7 days (14 total doses). The injections will be given as part of your hospital care for the stroke. Your doctors will monitor you closely during this time and track your recovery over the following weeks to see how well the treatment works compared to the placebo.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Shanghai Hutchison Pharmaceuticals Limited
Collaborators
Beijing Tiantan Hospital
Enrollment target
~1,096 participants
Started
December 2025
Primary completion
June 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wenwen Xu, Master
Beijing Tiantan Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.